Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer

Key Points

• To examine the treatment patterns in metastatic castration-resistant prostate cancer (mCRPC) following progression from metastatic hormone-sensitive prostate cancer (mHSPC).
• Analysis of treatment patterns for mCRPC after mHSPC management changes.
• Focus on first-line therapies, particularly androgen receptor pathway inhibitors (ARPIs).
• ARPIs were commonly used as the first-line therapy in mCRPC.
• Despite the availability of other treatments, their use remained limited even with clinical support.